Prestige Wealth Management Group’s Sarepta Therapeutics SRPT Stock Holding History

Prestige Wealth Management Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-28	Closed	-$479	–	1032
2025 Q2	$479	Buy	+28	New	+$1.2K	﹤0.01%	936
2023 Q4	–	Sell	-17	Closed	-$2.06K	–	1074
2023 Q3	$2.06K	Hold	17	–	–	﹤0.01%	731
2023 Q2	$1.95K	Hold	17	–	–	﹤0.01%	764
2023 Q1	$2.34K	Buy	17 +7	+70%	+$908	﹤0.01%	721
2022 Q4	$1.3K	Hold	10	–	–	﹤0.01%	927
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	914
2022 Q2	$1K	Sell	10 -26	-72%	-$1.91K	﹤0.01%	919
2022 Q1	$3K	Hold	36	–	–	﹤0.01%	731
2021 Q4	$3K	Buy	36 +1	+3%	+$85	﹤0.01%	749
2021 Q3	$3K	Hold	35	–	–	﹤0.01%	757
2021 Q2	$3K	Hold	35	–	–	﹤0.01%	752
2021 Q1	$3K	Buy	35 +14	+67%	+$1.29K	﹤0.01%	742
2020 Q4	$4K	Hold	21	–	–	﹤0.01%	647
2020 Q3	$3K	Hold	21	–	–	﹤0.01%	643
2020 Q2	$3K	Sell	21 -4	-16%	-$544	﹤0.01%	635
2020 Q1	$2K	Buy	+25	New	+$2.86K	﹤0.01%	674

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prestige Wealth Management Group's SRPT Position: Q3 2025 in Review

Prestige Wealth Management Group sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 28 shares — an estimated $479 sold.

Prestige Wealth Management Group first reported a position in SRPT in Q1 2020 and held it in 16 quarters. The position peaked at $4K in Q4 2020. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Prestige Wealth Management Group reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Prestige Wealth Management Group sold 28 Sarepta Therapeutics shares in Q3 2025, an estimated $479.
Prestige Wealth Management Group first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 16 quarters.
Prestige Wealth Management Group's Sarepta Therapeutics position peaked at $4K in Q4 2020.
319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Prestige Wealth Management Group's 13F filing for Q3 2025, filed 10 Nov 2025.